CHICAGO--(BUSINESS WIRE)--Dec. 15, 2005--Enrollment is under way for a new clinical trial to study the effectiveness of an investigational agent in patients with bronchioloalveolar carcinoma (BAC), a subtype of non-small cell lung cancer. The PEAK trial is a multicenter, open-label, phase II trial that will be led at Rush University Medical Center by Dr. Philip D. Bonomi, a leading oncology researcher who has participated in several studies of treatments for non-small cell lung cancer.
